These novel treatments, Semaglutide , represent a significant advancement in treating type 2 diabetes and conceivably other disorders. These drugs are categorized as GLP-1 receptor stimulators, meaning these substances to emulate the endogenous GLP-1 peptide, enhancing glucose release and reducin